<DOC>
	<DOCNO>NCT02054819</DOCNO>
	<brief_summary>It hypothesis protocol subset NSCLC patient stage IVa disease benefit curative therapy extend beyond limited subset oligometastatic patient already study .</brief_summary>
	<brief_title>Treating NSCLC Minimal Stage IV With Curative Intent</brief_title>
	<detailed_description>In study , patiently aggressively treat 4 cycle full dose platinum-based chemotherapy concurrent radiation therapy primary tumor identify mediastinal lymph nodal metastatic drainage . Local curative radiation target oligometastatic tumor site .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histological cytological document NSCLC , include squamous cell carcinoma , adenocarcinoma , large cell carcinoma include large cell neuroendocrine carcinoma poorly differentiate ( otherwise specify — NOS ) nonsmall cell lung cancer . Bronchial alveolar adenocarcinoma totally resected tumor exclude . All histology review East Carolina University designate participate center . Patients Stage IIIIIB intrathoracic disease oligometastatic disease ( hereafter refer `` Stage IVa '' disease ) eligible . Definition Stage IVa : Metastatic disease ; either biopsy proven strong radiographic evidence suggest existence . As determined CT , MRI PET five distinct metastatic site . All metastatic disease must anatomically locate way permit reasonable attempt permanent ablation . Ablative measure may include surgery , stereotactic radiosurgery , external beam therapy . Patients meet minimal metastatic disease requirement would otherwise staged II , IIIA IIIB . Patients tumor adjacent vertebral body eligible long gross disease encompass radiation boost field . Patients must ≥ 18 year age . Patients Zubrod ( ECOG ) performance status ≤ 2 . Adequate hematologic function define : absolute neutrophil count ( ANC ) ≥ 1000/mm3 , platelet ≥ 75,000/mm3 , hemoglobin ≥ 8 g/dL ( prior transfusion ) ; adequate hepatic function define : total bilirubin ≤ 3.0 mg/dl , adequate renal function define serum creatinine level ≤ 2.0 mg/dl . Forced expiratory volume ( FEV1 ) ≥ 800ml . Patients weight loss &lt; 20 % past 3 month . Patients pleural effusion proven cytologically negative small tap . Women childbearing potential must agree practice effective contraception throughout study plus four week . Pretreatment evaluation require eligibility include : A medical history , physical exam , Zubrod performance status within 3 week prior study entry . Complete blodd count ( CBC ) differential platelet count , laboratory profile must complete within 3 week prior study entry . FEV1 , CT scan chest whole body PET ( prefer ) , CT scan MRI ( prefer ) brain within 4 week prior study entry . For woman childbearing potential , serum urine pregnancy test within week prior start protocol treatment . Medical Oncology Radiation Oncology consultation approval . Patients must sign studyspecific consent form prior study entry . Prior systemic chemotherapy radiotherapy would interfere delivery treatment outline judged clinician . Cytologically malignant effusion . Metastatic disease beyond described section 3.1.2 . Active pulmonary infection responsive antimicrobial therapy . History symptomatic interstitial pneumonitis . Significant symptomatic cardiac disease , i.e. , unstable angina , uncompensated congestive heart failure , uncontrolled cardiac ventricular arrhythmia . Patients &gt; grade 2 neuropathy . Evidence malignancy past 2 year except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , situ cancer . Women pregnant breast feeding . Women childbearing potential unwilling practice effective contraception . Patients currently participate clinical trial and/or participate clinical trial previous 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>